Humoral and cellular immunity of two‐dose inactivated COVID‐19 vaccination in Chinese children: A prospective cohort study. Issue 1 (19th December 2022)
- Record Type:
- Journal Article
- Title:
- Humoral and cellular immunity of two‐dose inactivated COVID‐19 vaccination in Chinese children: A prospective cohort study. Issue 1 (19th December 2022)
- Main Title:
- Humoral and cellular immunity of two‐dose inactivated COVID‐19 vaccination in Chinese children: A prospective cohort study
- Authors:
- Wang, Hao
Gan, Mengze
Wu, Bihao
Zeng, Rui
Wang, Zhen
Xu, Jun
Li, Jia
Zhang, Yandi
Cao, Jinge
Chen, Li
Di, Dongsheng
Peng, Siyuan
Lei, Jinfeng
Zhao, Yingying
Song, Xuemei
Yuan, Tingting
Zhou, Tingting
Liu, Qian
Yi, Jing
Wang, Xi
Cai, Hao
Lei, Yanshou
Wen, Yuying
Li, Wenhui
Chen, Qinlin
Wang, Yufei
Long, Pinpin
Yuan, Yu
Wang, Chaolong
Pan, An
Wang, Qi
Gong, Rui
Fan, Xionglin
Wu, Tangchun
Liu, Li
… (more) - Abstract:
- Abstract: Children are the high‐risk group for COVID‐19, and in need of vaccination. However, humoral and cellular immune responses of COVID‐19 vaccine remain unclear in vaccinated children. To establish the rational immunization strategy of inactivated COVID‐19 vaccine for children, the immunogenicity of either one dose or two doses of the vaccine in children was evaluated. A prospective cohort study of 322 children receiving inactivated COVID‐19 vaccine was established in China. The baseline was conducted after 28 days of the first dose, and the follow‐up was conducted after 28 days of the second dose. The median titers of receptor binding domain (RBD)‐IgG, and neutralizing antibody (NAb) against prototype strain and Omicron variant after the second dose increased significantly compared to those after the first dose (first dose: 70.0, [interquartile range, 30.0–151.0] vs. second dose: 1261.0 [636.0–2060.0] for RBD‐IgG; 2.5 [2.5–18.6] vs. 252.0 [138.6–462.1] for NAb against prototype strain; 2.5 [2.5–2.5] vs. 15.0 [7.8–26.5] for NAb against Omicron variant, all p < 0.05). The flow cytometry results showed that the first dose elicited SARS‐CoV‐2 specific cellular immunity, while the second dose strengthened SARS‐CoV‐2 specific IL‐2 + or TNF‐α + monofunctional, IFN‐γ + TNF‐α + bifunctional, and IFN‐γ − IL‐2 + TNF‐α + multifunctional CD4 + T cell responses ( p < 0.05). Moreover, SARS‐CoV‐2 specific memory T cells were generated after the first vaccination, including theAbstract: Children are the high‐risk group for COVID‐19, and in need of vaccination. However, humoral and cellular immune responses of COVID‐19 vaccine remain unclear in vaccinated children. To establish the rational immunization strategy of inactivated COVID‐19 vaccine for children, the immunogenicity of either one dose or two doses of the vaccine in children was evaluated. A prospective cohort study of 322 children receiving inactivated COVID‐19 vaccine was established in China. The baseline was conducted after 28 days of the first dose, and the follow‐up was conducted after 28 days of the second dose. The median titers of receptor binding domain (RBD)‐IgG, and neutralizing antibody (NAb) against prototype strain and Omicron variant after the second dose increased significantly compared to those after the first dose (first dose: 70.0, [interquartile range, 30.0–151.0] vs. second dose: 1261.0 [636.0–2060.0] for RBD‐IgG; 2.5 [2.5–18.6] vs. 252.0 [138.6–462.1] for NAb against prototype strain; 2.5 [2.5–2.5] vs. 15.0 [7.8–26.5] for NAb against Omicron variant, all p < 0.05). The flow cytometry results showed that the first dose elicited SARS‐CoV‐2 specific cellular immunity, while the second dose strengthened SARS‐CoV‐2 specific IL‐2 + or TNF‐α + monofunctional, IFN‐γ + TNF‐α + bifunctional, and IFN‐γ − IL‐2 + TNF‐α + multifunctional CD4 + T cell responses ( p < 0.05). Moreover, SARS‐CoV‐2 specific memory T cells were generated after the first vaccination, including the central memory T cells and effector memory T cells. The present findings provide scientific evidence for the vaccination strategy of the inactive vaccines among children against COVID‐19 pandemic. … (more)
- Is Part Of:
- Journal of medical virology. Volume 95:Issue 1(2023)
- Journal:
- Journal of medical virology
- Issue:
- Volume 95:Issue 1(2023)
- Issue Display:
- Volume 95, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 95
- Issue:
- 1
- Issue Sort Value:
- 2023-0095-0001-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-12-19
- Subjects:
- children -- inactivated COVID‐19 vaccine -- neutralizing antibody -- T cell responses
Virology -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-9071 ↗
http://www.interscience.wiley.com/jpages/0146-6615 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jmv.28380 ↗
- Languages:
- English
- ISSNs:
- 0146-6615
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5017.095000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25170.xml